PMID- 20875357
OWN - NLM
STAT- MEDLINE
DCOM- 20110217
LR  - 20190918
IS  - 1579-2242 (Electronic)
IS  - 0300-8932 (Linking)
VI  - 63
IP  - 10
DP  - 2010 Oct
TI  - Soluble ST2 monitoring provides additional risk stratification for outpatients 
      with decompensated heart failure.
PG  - 1171-8
AB  - INTRODUCTION AND OBJECTIVES: The novel biomarker ST2 provides diagnostic 
      information in a variety of clinical settings. The objective was to determine 
      whether measurement of the soluble ST2 (sST2) concentration improves risk 
      stratification in outpatients with decompensated heart failure (HF). METHODS: The 
      concentrations of sST2 and N-terminal probrain natriuretic peptide (NT-proBNP) 
      and a heart failure severity score (HFSS), based on Framingham criteria, were 
      determined at baseline and 2 weeks later in 48 outpatients with decompensated hf. 
      The ratio of the value of each variable at week 2 relative to baseline was 
      determined. Patients were followed for 1 year and cardiac events (i.e. death, HF 
      admission and heart transplantation) were recorded. RESULTS: By 1 year, 56% of 
      patients had experienced a cardiac event. The sST2 ratio was significantly lower 
      in patients who did not have a cardiac event (0.6 +/- 0.39 vs. 1.39 +/- 0.92; P< 
      .001). After multivariable adjustment, the sST2 ratio remained an independent 
      predictor of risk (odds ratio=1.054; 95% confidence interval, 1.01-1.09; P=.017). 
      The optimum cut-point for the sST2 ratio determined by receiver operating curve 
      [ROC] analysis was 0.75; this accounted for 25% of the change in sST2 by week 2. 
      Among patients with an sST2 ratio >0.75 and a baseline NT-proBNP level >1000 
      ng/L, 72% had a cardiac event (P=.018), while no events occurred in patients with 
      marker values below these reference levels. CONCLUSIONS: Determination of the 
      sST2 concentration in serial samples provided additional risk stratification in 
      outpatients with decompensated HF. Repeated measurement of sST2 may aid clinical 
      decision-making.
FAU - Bayes-Genis, Antoni
AU  - Bayes-Genis A
AD  - Servicio de Cardiologia, Hospital Universitari Germans Trias i Pujol, Badalona, 
      Barcelona, Espana. abayesgenis@gmail.com
FAU - Pascual-Figal, Domingo
AU  - Pascual-Figal D
FAU - Januzzi, James L
AU  - Januzzi JL
FAU - Maisel, Alan
AU  - Maisel A
FAU - Casas, Teresa
AU  - Casas T
FAU - Valdes Chavarri, Mariano
AU  - Valdes Chavarri M
FAU - Ordonez-Llanos, Jordi
AU  - Ordonez-Llanos J
LA  - eng
LA  - spa
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Spain
TA  - Rev Esp Cardiol
JT  - Revista espanola de cardiologia
JID - 0404277
RN  - 0 (Biomarkers)
RN  - 0 (IL1RL1 protein, human)
RN  - 0 (Interleukin-1 Receptor-Like 1 Protein)
RN  - 0 (Peptide Fragments)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Area Under Curve
MH  - Biomarkers
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*diagnosis/diagnostic imaging/surgery
MH  - Heart Transplantation
MH  - Humans
MH  - Interleukin-1 Receptor-Like 1 Protein
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Outpatients
MH  - Peptide Fragments/blood
MH  - ROC Curve
MH  - Receptors, Cell Surface/*blood
MH  - Regression Analysis
MH  - Risk Assessment
MH  - Stroke Volume/physiology
MH  - Treatment Outcome
MH  - Ultrasonography
EDAT- 2010/09/30 06:00
MHDA- 2011/02/18 06:00
CRDT- 2010/09/30 06:00
PHST- 2010/09/30 06:00 [entrez]
PHST- 2010/09/30 06:00 [pubmed]
PHST- 2011/02/18 06:00 [medline]
AID - 13155724 [pii]
AID - 10.1016/s1885-5857(10)70231-0 [doi]
PST - ppublish
SO  - Rev Esp Cardiol. 2010 Oct;63(10):1171-8. doi: 10.1016/s1885-5857(10)70231-0.